Sign in
CompletedPhase 1/2

A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults

Key facts

Who runs it
ModernaTX, Inc.
Where
Annapolis, Austin, Baton Rouge, Beaumont, Brookline, Chandler, Charleston, Charlotte, Cincinnati, Colton, Columbus, Dayton, Dearborn Heights, Decatur, DeLand, Elizabethton, Fort Worth, Gulfport, Hampton, Hendersonville, Hollywood, Houston, Huntington Beach, Inverness, Jacksonville, Kansas City, Las Vegas, Lenexa, Lilburn, Lincoln, Longmont, Maitland, McKinney, Metairie, Miami, Modesto, Morton, Myrtle Beach, New Orleans, Norfolk, North Las Vegas, Oklahoma City, Peoria, Philadelphia, Pleasant View, Portsmouth, Prairieville, River Forest, Rochester, Rockville, Roy, Sacramento, Salt Lake City, San Angelo, San Antonio, Tulsa, Versailles, Wenatchee, Wichita, Wilmington, and Yukon, United StatesSee the 67 sites
Trial code
Status
Completed
Phase
Phase 1/2
People taking part
1,758 people enrolled
Started
14 Apr 2023
Ended
3 Dec 2024
Type of study
Interventional, 30 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Influenza Vaccine 1
  • mRNA-1083.1
  • mRNA-1083.2
  • mRNA-1083.3
  • Investigational Influenza Vaccine 1
  • Investigational COVID-19 Vaccine 1
  • COVID-19 Vaccine 1
  • Investigational Influenza Vaccine 2
  • Influenza Vaccine 2
  • mRNA-1083
  • Investigational COVID-19 Vaccine 2
  • COVID-19 Vaccine 2
Record updated
23 December 2025

Who can take part

Age
18 years to 79 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Part 1 (Phase 1/2)
  • Adults ≥18 to <80 years of age at the time of consent
  • Body mass index (BMI) of 18 kilograms (kg)/square meter (m\^2) to 35 kg/m\^2 (inclusive) at the Screening Visit
  • Healthy as determined by medical evaluation, including medical history, physical examination, and laboratory tests
  • For female participants of childbearing potential: negative pregnancy test, adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to Day 1, agreement to continue adequate contraception through 90 days following vaccine administration, and not currently breastfeeding
  • Fully vaccinated for COVID-19 primary series according to the locally authorized or approved regimen, and their last COVID-19 vaccine (primary series or booster) was ≥120 days prior to Day 1; Part 2 (Phase 2 Extension)
  • Adults ≥18 to <50 years of age at the time of consent
  • BMI of 18 kg/m\^2 to 35 kg/m\^2 (inclusive) at the Screening Visit
  • Healthy as determined by medical evaluation, including medical history, and physical examination
  • For female participants of childbearing potential: negative pregnancy test, adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to Day 1, agreement to continue adequate contraception through 90 days following vaccine administration, and not currently breastfeeding
  • Have received at least 2 doses of locally authorized or approved COVID-19 vaccines and last dose was ≥90 days prior to Day 1

Who cannot take part

  • Participant is acutely ill or febrile (temperature ≥38.0 degrees Celsius [°C]/100.4 degrees Fahrenheit [°F]) 72 hours prior to or at the Screening Visit or Day 1
  • Participant has received systemic immunosuppressants for >14 days in total within 180 days prior to Screening Visit (for glucocorticoids ≥10 milligrams [mg]/day of prednisone or equivalent) or is anticipating the need for systemic immunosuppressive treatment at any time during participation in the clinical trial (including intra-articular steroid injections). Inhaled, nasal, and topical steroids are allowed
  • Participant has received or plans to receive any vaccine authorized or approved by a local health agency ≤28 days prior to study intervention administration or plans to receive a vaccine authorized or approved by a local health agency within 28 days after study intervention administration
  • Participant has received a seasonal influenza vaccine or any other investigational influenza vaccine within 150 days prior to Day 1
  • Participant tested positive for influenza by local health authority-approved testing methods ≤150 days prior to Day 1
  • Participant has had close contact to someone with COVID-19 as defined by the Centers for Disease Control and Prevention (CDC) in the past 10 days prior to Day 1
  • Participant has donated ≥450 milliliters (mL) of blood products within 28 days prior to the Screening Visit or plans to donate blood products during the clinical trial
  • Any medical, psychiatric, or occupational condition, including reported history of drug or alcohol abuse, that, in the opinion of the Investigator, might pose additional risk due to participation in the clinical trial or could interfere with the interpretation of study results
  • Part 1 (Phase 1/2) and Part 2 (Phase 2 Extension)
  • Working or has worked as study personnel, is an immediate family member or household member of study personnel, study site staff, or Sponsor personnel, or resides in a nursing home; Part 2 (Phase 2 Extension) Only
  • Participants who enrolled in Part 1 of the mRNA-1083-P101 (Phase 1/2) study; Note: Other inclusion/exclusion criteria may apply

Where in United States

  • Annapolis Internal MedicineAnnapolis, United States
  • Benchmark ResearchAustin, United States
  • Tekton ResearchAustin, United States
  • Velocity Clinical ResearchBaton Rouge, United States
  • Tekton ResearchBeaumont, United States
  • DM Clinical ResearchBrookline, United States
  • Chandler Clinical TrialsChandler, United States
  • DelRicht ResearchCharleston, United States
  • Tryon Medical PartnersCharlotte, United States
  • CTI Clinical Research CenterCincinnati, United States
  • Velocity Clinical ResearchCincinnati, United States
  • Benchmark ResearchColton, United States
  • Centricity ResearchColumbus, United States
  • WellNow Urgent Care & ResearchDayton, United States
  • Vida Clinical StudiesDearborn Heights, United States
  • Decatur, GeorgiaHospital not named in the registry
  • CenExel iResearchDecatur, United States
  • DeLand, FloridaHospital not named in the registry
  • Medical CareElizabethton, United States
  • Benchmark ResearchFort Worth, United States
  • DelRicht ResearchGulfport, United States
  • Meridian Clinical ResearchHampton, United States
  • DelRicht ResearchHendersonville, United States
  • CenExelHollywood, United States
  • Cyfair Clinical ResearchHouston, United States
  • Texas Center for Drug DevelopmentHouston, United States
  • Marvel Clinical ResearchHuntington Beach, United States
  • Nature Coast Clinical ResearchInverness, United States
  • Jacksonville Center for Clinical ResearchJacksonville, United States
  • Clay Platte Family MedicineKansas City, United States
  • CCT ResearchLas Vegas, United States
  • Excel Clinical ResearchLas Vegas, United States
  • Johnson County Clin-TrialsLenexa, United States
  • Lifeline Primary CareLilburn, United States
  • Velocity Clinical ResearchLincoln, United States
  • Tekton ResearchLongmont, United States
  • Maitland, FloridaHospital not named in the registry
  • DelRicht ResearchMcKinney, United States
  • Benchmark ResearchMetairie, United States
  • Suncoast Research GroupMiami, United States
  • Central Valley ResearchModesto, United States
  • Koch Family MedicineMorton, United States
  • Trial Management AssociatesMyrtle Beach, United States
  • Delricht ResearchNew Orleans, United States
  • Velocity Clinical ResearchNorfolk, United States
  • Las Vegas Clinical TrialsNorth Las Vegas, United States
  • Lynn Institute of East OklahomaOklahoma City, United States
  • Optimal ResearchPeoria, United States
  • DM Clinical ResearchPhiladelphia, United States
  • Mercado Medical PracticePhiladelphia, United States
  • CCT ResearchPleasant View, United States
  • Velocity Clinical ResearchPortsmouth, United States
  • DelRicht ResearchPrairieville, United States
  • DM Clinical ResearchRiver Forest, United States
  • Rochester Clinical ResearchRochester, United States
  • Velocity Clinical ResearchRockville, United States
  • Ogden ClinicRoy, United States
  • Benchmark ResearchSacramento, United States
  • JBR Clinical ResearchSalt Lake City, United States
  • Benchmark ResearchSan Angelo, United States
  • Tekton ResearchSan Antonio, United States
  • DelRicht ResearchTulsa, United States
  • Versailles Family MedicineVersailles, United States
  • Wenatchee Valley Hospital & Clinics CampusWenatchee, United States
  • Tekton ResearchWichita, United States
  • Trial Management AssociatesWilmington, United States
  • Tekton Research, Inc.Yukon, United States

About the trial

What the trial wants to find out

The study is divided into 2 parts: Part 1 and Part 2. The purpose of Part 1 of this study is to generate sufficient safety, reactogenicity, and immunogenicity data to enable selection of an mRNA-1083 vaccine composition and dose level to evaluate in a subsequent Phase 3 clinical trial in adults.

Read full original descriptionShow less

The purpose of Part 2 of this study is to generate safety and immunogenicity data for additional mRNA-1083 compositions and dose levels in young adults ≥18 years and <50 years of age.

The 30 groups in the trial

  • Part 1 Cohort A2: mRNA-1083.1 Dose BTreatment being tested

    Participants will receive single intramuscular (IM) injection of mRNA-1083.1 at Dose Level B on Day 1.

    Treatment: mRNA-1083.1

  • Part 1 Cohort A3: mRNA-1083.1 Dose CTreatment being tested

    Participants will receive single IM injection of mRNA-1083.1 at Dose Level C on Day 1.

    Treatment: mRNA-1083.1

  • Part 1 Cohort A4: mRNA-1083.2 Dose ATreatment being tested

    Participants will receive single IM injection of mRNA-1083.2 at Dose Level A on Day 1.

    Treatment: mRNA-1083.2

  • Part 1 Cohort A5: mRNA-1083.2 Dose BTreatment being tested

    Participants will receive single IM injection of mRNA-1083.2 at Dose Level B on Day 1.

    Treatment: mRNA-1083.2

  • Part 1 Cohort A6: mRNA-1083.2 Dose CTreatment being tested

    Participants will receive single IM injection of mRNA-1083.2 at Dose Level C on Day 1.

    Treatment: mRNA-1083.2

  • Part 1 Cohort A7: mRNA-1083.3Treatment being tested

    Participants will receive single IM injection of mRNA-1083.3 on Day 1.

    Treatment: mRNA-1083.3

  • Part 1 Cohort A8: Investigational Influenza Vaccine 1Existing treatment, for comparison

    Participants will receive single IM injection of Investigational Influenza Vaccine 1 on Day 1.

    Treatment: Investigational Influenza Vaccine 1

  • Part 1 Cohort A9: Investigational COVID-19 Vaccine 1Existing treatment, for comparison

    Participants will receive single IM injection of Investigational COVID-19 Vaccine 1 on Day 1.

    Treatment: Investigational COVID-19 Vaccine 1

  • Part 1 Cohort A10: COVID-19 Vaccine 1Existing treatment, for comparison

    Participants will receive single IM injection of COVID-19 Vaccine 1 on Day 1.

    Treatment: COVID-19 Vaccine 1

  • Part 1 Cohort A11: Investigational Influenza Vaccine 2Existing treatment, for comparison

    Participants will receive single IM injection of Investigational Influenza Vaccine 2 on Day 1.

    Treatment: Investigational Influenza Vaccine 2

  • Part 1 Cohort A12: Influenza Vaccine 1Existing treatment, for comparison

    Participants will receive single IM injection of Influenza Vaccine 1 on Day 1.

    Treatment: Influenza Vaccine 1

  • Part 1 Cohort A13: Influenza Vaccine 2Existing treatment, for comparison

    Participants will receive single IM injection of Influenza Vaccine 2 on Day 1.

    Treatment: Influenza Vaccine 2

  • Part 1 Cohort B1: mRNA-1083.1 Dose ATreatment being tested

    Participants will receive single IM injection of mRNA-1083.1 at Dose Level A on Day 1.

    Treatment: mRNA-1083.1

  • Part 1 Cohort B2: mRNA-1083.1 Dose BTreatment being tested

    Participants will receive single IM injection of mRNA-1083.1 at Dose Level B on Day 1.

    Treatment: mRNA-1083.1

  • Part 1 Cohort B3: mRNA-1083.1 Dose CTreatment being tested

    Participants will receive single IM injection of mRNA-1083.1 at Dose Level C on Day 1.

    Treatment: mRNA-1083.1

  • Part 1 Cohort B4: mRNA-1083.2 Dose ATreatment being tested

    Participants will receive single IM injection of mRNA-1083.2 at Dose Level A on Day 1.

    Treatment: mRNA-1083.2

  • Part 1 Cohort B5: mRNA-1083.2 Dose BTreatment being tested

    Participants will receive single IM injection of mRNA-1083.2 at Dose Level B on Day 1.

    Treatment: mRNA-1083.2

  • Part 1 Cohort B6: mRNA-1083.2 Dose CTreatment being tested

    Participants will receive single IM injection of mRNA-1083.2 at Dose Level C on Day 1.

    Treatment: mRNA-1083.2

  • Part 1 Cohort B7: mRNA-1083.3Treatment being tested

    Participants will receive single IM injection of mRNA-1083.3 on Day 1.

    Treatment: mRNA-1083.3

  • Part 1 Cohort B8: Investigational Influenza Vaccine 1Existing treatment, for comparison

    Participants will receive single IM injection of Investigational Influenza Vaccine 1 on Day 1.

    Treatment: Investigational Influenza Vaccine 1

  • Part 1 Cohort B9: Investigational COVID-19 Vaccine 1Existing treatment, for comparison

    Participants will receive single IM injection of Investigational COVID-19 Vaccine 1 on Day 1.

    Treatment: Investigational COVID-19 Vaccine 1

  • Part 1 Cohort B10: COVID-19 Vaccine 1Existing treatment, for comparison

    Participants will receive single IM injection of COVID-19 Vaccine 1 on Day 1.

    Treatment: COVID-19 Vaccine 1

  • Part 1 Cohort B11: Investigational Influenza Vaccine 2Existing treatment, for comparison

    Participants will receive single IM injection of Investigational Influenza Vaccine 2 on Day 1.

    Treatment: Investigational Influenza Vaccine 2

  • Part 1 Cohort B12: Influenza Vaccine 1Existing treatment, for comparison

    Participants will receive single IM injection of Influenza Vaccine 1 on Day 1.

    Treatment: Influenza Vaccine 1

  • Part 2: mRNA-1083 Composition 1 Dose ATreatment being tested

    Participants will receive single IM injection of mRNA-1083 Composition 1 at Dose Level A on Day 1.

    Treatment: mRNA-1083

  • Part 2: mRNA-1083 Composition 2 Dose ATreatment being tested

    Participants will receive single IM injection of mRNA-1083 Composition 2 at Dose Level A on Day 1.

    Treatment: mRNA-1083

  • Part 2: mRNA-1083 Composition 1 Dose BTreatment being tested

    Participants will receive single IM injection of mRNA-1083 Composition 1 at Dose Level B on Day 1.

    Treatment: mRNA-1083

  • Part 2: mRNA-1083 Composition 2 Dose BTreatment being tested

    Participants will receive single IM injection of mRNA-1083 Composition 2 at Dose Level B on Day 1.

    Treatment: mRNA-1083

  • Part 2: mRNA-1083 Composition 1 Dose CTreatment being tested

    Participants will receive single IM injection of mRNA-1083 Composition 1 at Dose Level C on Day 1.

    Treatment: mRNA-1083

  • Part 2: mRNA-1083 Composition 2 Dose CTreatment being tested

    Participants will receive single IM injection of mRNA-1083 Composition 2 at Dose Level C on Day 1.

    Treatment: mRNA-1083

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1/2, Randomized, Observer-blind, Active-Control Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-based Influenza and SARS-CoV-2 Multi-component Vaccines in Healthy Adults
Publications
Record updated
23 December 2025